Short answer
STANDARD BIOTOOLS INC. (LAB) filed an 8-K current report with the SEC on July 28, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Illumina paid Standard BioTools approximately $30 million cash for waiving the 2026 earnout and terminating royalty and license agreements.
STANDARD BIOTOOLS INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Illumina paid Standard BioTools approximately $30 million cash for waiving the 2026 earnout and terminating royalty and license agreements
- Agreement exchanges future SOMAmer-related earnout and royalty streams for immediate liquidity, eliminating potential recurring revenue
- Multiplex Bio agreed to acquire the mass cytometry business for $5 million, payable entirely through a 6% promissory note maturing five years after closing
- Standard BioTools may receive an additional $5 million if Multiplex Bio completes a qualifying sale within 10 years
- Company may need to provide Multiplex Bio up to $10 million in working-capital financing if third-party funding is unavailable
Item 7.01 · Regulation FD Disclosure
- Disclosure ties Standard BioTools to pending Mass Cytometry disposition and Treeline transaction
- Both transactions require stockholder approval and remain subject to closing conditions
- Treeline transaction benefits, timing, and combined-company outlook remain uncertain
- Potential risks include termination fees, litigation costs, unexpected liabilities, and Nasdaq delisting
- Investors directed to Form S-4, proxy materials, and subsequent SEC filings before voting decisions
Item EX-99.1 · Exhibit EX-99.1
- Mass Cytometry business sale to Multiplex Bio valued up to $10 million, including seller’s note and potential milestone payment
- Standard BioTools to provide Multiplex Bio up to $10 million working-capital loan, limiting near-term cash proceeds
- Approximately $30 million Illumina earnout and royalty buyout increases pro forma net cash used in Treeline merger exchange-ratio calculations
- Mass Cytometry sale expected by end-2026, preserving CyTOF and Hyperion customer relationships, team, and service commitments
- FTC early termination clears antitrust waiting period; Treeline merger still requires stockholder approval and other closing conditions
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other STANDARD BIOTOOLS INC. 8-K filings
Get the next LAB 8-K as it lands
Follow LAB for push alerts, or ask the research agent what this filing means.